Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2026-05-18 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
生物股份关于回购注销部分股票（暨减少注册资本）通知债权人的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement by 金宇生物技术股份有限公司 regarding the repurchase (buyback) and cancellation of treasury shares, resulting in a reduction of the company’s registered capital, and it notifies creditors of their rights following the capital reduction. This is not a financial report itself but a corporate action announcement involving share repurchase and capital change. Per the classification definitions, this fits “Share Issue/Capital Change” (Code: SHA).
2026-05-18 Chinese
金宇生物技术股份有限公司2025年年度股东会法律意见书
Regulatory Filings Classification · 92% confidence The document is a legal opinion letter from an external law firm confirming the legality of the procedures and voting results for the company’s 2025 Annual Shareholders’ Meeting. It does not contain substantive financial statements, is not a meeting presentation or minutes, but rather a lawyer’s certification/attestation. Under the Certification Rule, such attestation letters are classified as general Regulatory Filings (RNS).
2026-05-18 Chinese
生物股份关于股东股份质押的公告
Regulatory Filings Classification · 88% confidence The document is an exchange filing disclosing a shareholder’s pledge of shares as collateral. It contains no financial statements, no share repurchase/purchase by the company, no dividend, no AGM materials, no financing by the company, and does not fit any specific category for share issuance or major shareholding threshold crossing. It is therefore a general regulatory disclosure. According to the rules, this is classified under Regulatory Filings (RNS).
2026-05-12 Chinese
生物股份关于召开2025年年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 85% confidence The document is a company announcement (公告) detailing the date, venue, agenda, and participation instructions for an upcoming investor “业绩说明会” (earnings explanation meeting/investor presentation) covering the 2025 annual results and 2026 Q1 performance. There are no financial statements or actual results disclosed here—rather it is an invitation and agenda for a presentation session. This fits the “Investor Presentation (IP)” category, which covers announcements and materials for investor-focused presentations on financial performance and strategy.
2026-05-12 Chinese
生物股份2025年年度股东会会议资料（修订后）
AGM Information Classification · 92% confidence The document is titled “2025年年度股东会会议资料” and contains the full agenda and proposal materials (board work report, annual report summary, profit distribution plan, guarantee proposal, share repurchase/cancellation plan, articles amendment, director remuneration plan, etc.) prepared for and shared with shareholders at the 2025 Annual General Meeting. It is not the annual report itself, nor simply a notice of report publication, but the actual meeting materials presented at the AGM. Therefore, it falls squarely under AGM Information (Code: AGM-R).
2026-05-12 Chinese
金宇生物技术股份有限公司章程（2026年5月修订）
Governance Information Classification · 92% confidence The document is the full company constitution (章程) of Jin Yu Bio-Technology Co., detailing its articles of association, board structure, shareholders’ meetings, voting procedures, and other internal governance rules. This aligns with the definition of Governance Information (CGR).
2026-05-12 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.